Citi Upgrades Gilead Sciences (GILD) to Buy, Raises Target to $49

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. TSLA
4. NVDA
5. GNK
6. USO
7. AWK
8. ARGX
9. AZN
10. SPCX

November 21, 2011 10:06 AM EST
Get Alerts GILD Hot Sheet
Price: $138.92 +0.40%

Rating Summary:
    36 Buy, 7 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Amid an 11 percent decline in shares of Gilead Sciences (NASDAQ: GILD) Monday on the heels of news the company will acquire Pharmasset (Nasdaq: VRUS) for an 89 percent premium, Citi's Yarn Werber has upgraded the stock.

Werber now rates Gilead shares a Buy, up from Neutral previously. The firm's new price target is $49, up from $45 previously.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Upgrades

Related Entities

Citi